5 results about "Cancer targeting" patented technology

Recombinant polynucleotides and vectors containing an engineered (artificial) exon-intron-exon gene structure in a transgene are provided, which undergoes splicing when it is expressed in a target cell.

Provided herein is a composition comprising, a cell, comprising nucleic acids encoding a chimeric antigen receptor (CAR) and one or more of signaling proteins selected from K13-vFLIP, MC159-vFLIP, cFLIP-L, cFLIP-p22, HTLV1-Tax and HTLV2-Tax, wherein the CAR comprises an a) extracellular antigen specific domain, b) a transmembrane domain and c) an intracellular signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM); wherein c) is located at the C-terminus of the chimeric receptor. In some embodiments, the CAR further comprises one or more co-stimulatory domains. Also provided herein are methods for treating diseases using the compositions described herein. Further provided herein is a kinase inhibitor for use in therapeutic methods described herein.

To provide a method for treating the target cancer. [Solution] A method for treating a target cancer, comprising administering a bispecific antibody having binding specificity to EGFR and HER3 and a therapeutic agent to the target, wherein the therapeutic agent includes a tyrosine kinase inhibitor (TKI), an alkylating agent, an antimetabolite, a microtubule inhibitor, an anti-cancer antibiotic, a topoisomerase inhibitor, a chemoprotective agent, or a combination thereof.

Disclosed herein are multivalent, multispecific single-chain antibodies having specificity for four antigens selected from the group consisting of EGFR, PD-L1, HSA, CD28, CD3E, OX-40, CD40, 4-1BB, LAG3, and CD16A.

The present invention relates to uses of an anti-hGDF-15 antibody for the treatment of cancer in a patient in combination with a cancer antigen-targeted drug conjugate, such as an antibody-drug conjugate, that induces cancer cell stress.